Abbott Laboratories (NYSE:ABT) is Silver Lake Advisory LLC’s 7th Largest Position

Silver Lake Advisory LLC increased its holdings in Abbott Laboratories (NYSE:ABT) by 5.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,868 shares of the healthcare product maker’s stock after acquiring an additional 2,492 shares during the quarter. Abbott Laboratories comprises approximately 3.1% of Silver Lake Advisory LLC’s portfolio, making the stock its 7th biggest position. Silver Lake Advisory LLC’s holdings in Abbott Laboratories were worth $5,599,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Stuart Chaussee & Associates Inc. lifted its position in Abbott Laboratories by 236.0% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 336 shares of the healthcare product maker’s stock valued at $37,000 after acquiring an additional 236 shares in the last quarter. Rise Advisors LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $37,000. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of Abbott Laboratories in the third quarter worth approximately $40,000. Cornerstone Planning Group LLC grew its position in Abbott Laboratories by 79.4% during the third quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after buying an additional 201 shares during the period. Finally, Bfsg LLC bought a new position in Abbott Laboratories in the fourth quarter worth approximately $51,000. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Barclays reduced their price objective on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, April 22nd. Citigroup raised their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada reduced their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, April 18th. Raymond James reissued a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a report on Wednesday, April 24th. Finally, Evercore ISI boosted their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $121.50.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now directly owns 78,704 shares in the company, valued at approximately $9,444,480. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares of the company’s stock, valued at approximately $9,444,480. The disclosure for this sale can be found here. Insiders sold 13,935 shares of company stock valued at $1,670,048 in the last 90 days. Company insiders own 1.10% of the company’s stock.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock traded down $0.99 on Thursday, hitting $105.30. The company’s stock had a trading volume of 1,314,287 shares, compared to its average volume of 5,556,161. The company has a market capitalization of $182.71 billion, a price-to-earnings ratio of 32.80, a price-to-earnings-growth ratio of 2.55 and a beta of 0.76. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64. The firm has a fifty day moving average price of $113.06 and a 200-day moving average price of $108.43. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. The firm had revenue of $9.96 billion during the quarter, compared to analysts’ expectations of $9.88 billion. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.03 earnings per share. As a group, sell-side analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 68.54%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.